Facebook
Twitter
LinkedIn
Forward
Section 1: Introduction to Antimicrobial Stewardship (Faculty)
Section 1: Introduction to Antimicrobial Stewardship
Content in this section covers 3 main topics. These include:
- An Introduction to Antimicrobial Stewardship
- A Brief Overview of the Side Effects of Antibiotics, and
- The Role of Diagnostics in Antimicrobial Stewardship
As the faculty or stewardship champion leading this effort, you can decide how the content is distributed and presented to your stewards- in- training.
For Stewards:
The fellow/trainee can watch the eLearning on their own, followed by a debrief between fellow and faculty.
For Faculty:
To present in a classroom or small group setting, there are two methods of delivery:
Method 1: | You can open the eLearning and let it talk for you, controlling the slides and the pace |
Method 2: | You can open the video,narrating the slides yourself. Pdf slide notes are also available |
At the bottom of this course landing page, you will find a handout highlighting AS Core Concepts that are introduced in this section. Knowledge check questions embedded in the eLearnings and presentations provide a mechanism to assess understanding of concepts.
Target Audience
Program Directors, Antimicrobial Stewardship Faculty Champions, and additional Faculty responsible for leading and implementing the CAS Curriculum.
Learning Objectives
Upon completion of this section, stewards- in- training will be able to:
- Define antimicrobial stewardship, its programmatic goals, and key strategies to achieve the goals
- Relate trends and patterns between antimicrobial use and resistance
- Recognize adverse events associated with the use of specific antimicrobials, including the risk for development of C. difficile infections
- Describe the role of clinical and laboratory diagnostic tools in improving antimicrobial use
- Define expected outcomes of an ASP
Additional Information
| Attachment | Size |
|---|---|
 2019 AS Core Concepts | 121.44 KB |
| 2019 AS Clinical Teaching Tool | 146.95 KB |
AS Curriculum Workgroup COI Summary Reviewed April 2017 by Rachel Simmons, MD No conflicts found
| Name | Individual's Role in Activity | Name of Commercial Interest | Nature of Relationship |
|---|---|---|---|
| Abbo, Lillian | Workgroup member | Pfizer Brazil | Honoraria |
| Advani, Sonali | Workgroup member | Nabriva Therapeutics | Advisory/Consultant Role |
| Amstrong, Wendy | Workgroup member | None | |
| Barsoumian, Alice | Workgroup member | None | |
| Beeler, Cole | Workgroup member | None | |
| Bystritsky, Rachel | Workgroup member | None | |
| Cherabuddi, Kartik | Workgroup member | Gatorade | Start - up Research Fund |
| NIH (Medimmune) | Research Grant | ||
| Cohen, Seth | Workgroup member | None | |
| Hamilton, Keith | Workgroup member | None | |
| Ince, Dilek | Workgroup member | Ansun Pharma | Research Grant |
| Justo, Julie Ann | Workgroup member | None | |
| Logan, Ashleigh | Staff | None | |
| Luther, Vera | Workgroup member | None | |
| Lynch, John | Workgroup member | Astellas Pharmaceuticals, Juno Therapeutics | Advisory/Consultant Role |
| Nori, Priya | Workgroup member | None | |
| Ohl, Christopher | Workgroup member | Paratek, Bayer, Cempra Pharmaceuticals | Advisory/Consultant Role |
| Patel, Payal | Workgroup member | None | |
| Pottinger, Paul | Workgroup member | McGraw Hill, Elsevier | Honoraria |
| Schwartz, Brian | Workgroup member | None | |
| Spicer, Jennifer | Workgroup member | None | |
| Stack, Conor | Workgroup member | None | |
| Zhou, Yuan | Workgroup member | None | |
| Shnekendorf, Rachel | Staff | None |